SACRAMENTO, Calif. & SAN FRANCISCO & SAN DIEGO--(BUSINESS WIRE)--California Life Sciences Association (CLSA), the premier public policy advocacy and business leadership trade association representing California’s life sciences industry, today issued the following statement applauding the passage of California’s 2017-2018 budget that invests $10 million in the California Initiative to Advance Precision Medicine (CIAPM). This statement can be attributed to Sara Radcliffe, President & CEO, CLSA:
“California Life Sciences Association (CLSA) applauds Governor Jerry Brown, California State Senate and California Assembly leaders for their strong support of life sciences innovation, as demonstrated again in this year’s 2017-2018 budget deal which allocates a $10 million investment in precision medicine research. California is the birthplace of biotechnology and today the state’s life sciences sector employs over 287,200 people working to develop innovative new medicines, technologies and therapies needed to treat and cure patients.
“We look forward to working with the Governor's Office of Planning and Research to help universities and our life science member companies engage in public-private partnerships and apply these research dollars to build the scientific infrastructure necessary to advance precision medicine. Many CLSA member companies, universities and research institutes are already working in the precision medicine space to improve health outcomes for patients and we applaud Governor Brown and legislative leaders for their thoughtful and visionary support to advance this important research in California.”
To learn more about California’s treasured life sciences industry, visit www.CALifeSciencesIndustry.com.
About California Life Sciences Association (CLSA)
California Life Sciences Association (CLSA) is the state’s largest and most influential life sciences advocacy and business leadership organization. With offices in Sacramento, San Diego, South San Francisco, Los Angeles and Washington DC, CLSA works closely with industry, government, academia and others to shape public policy, improve access to innovative technologies and grow California’s life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device and diagnostics companies, research universities and institutes, investors and service providers throughout the Golden State. CLSA was founded in 2015 when the Bay Area Bioscience Association (BayBio) and the California Healthcare Institute (CHI) merged. Visit CLSA at www.califesciences.org, and follow us on Twitter @CALifeSciences, Facebook, Instagram, LinkedIn and YouTube.